178 related articles for article (PubMed ID: 33376433)
1. Serum Tumor Marker Dynamics as Predictive Biomarkers in NSCLC Chemo-Immunotherapy and Mono-Immunotherapy Maintenance: A Registry-Based Descriptive Study.
Lang D; Haslinger W; Akbari K; Scala M; Hergan B; Asel C; Horner A; Wass R; Brehm E; Kaiser B; Lamprecht B
Lung Cancer (Auckl); 2020; 11():113-121. PubMed ID: 33376433
[TBL] [Abstract][Full Text] [Related]
2. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
3. Sex-Based Clinical Outcome in Advanced NSCLC Patients Undergoing PD-1/PD-L1 Inhibitor Therapy-A Retrospective Bi-Centric Cohort Study.
Lang D; Brauner A; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Kaiser B; Greil R; Lamprecht B
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008255
[TBL] [Abstract][Full Text] [Related]
4. Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study.
Huang J; Xiao Y; Zhou Y; Deng H; Yuan Z; Dong L; Lan J; Li X; Liu G; Hu H; Huang S; Yang X
BMC Cancer; 2023 Aug; 23(1):812. PubMed ID: 37649021
[TBL] [Abstract][Full Text] [Related]
5. Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy.
Uehara Y; Hakozaki T; Kitadai R; Narita K; Watanabe K; Hashimoto K; Kawai S; Yomota M; Hosomi Y
Transl Lung Cancer Res; 2022 Feb; 11(2):135-149. PubMed ID: 35280320
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Mazieres J; Drilon A; Lusque A; Mhanna L; Cortot AB; Mezquita L; Thai AA; Mascaux C; Couraud S; Veillon R; Van den Heuvel M; Neal J; Peled N; Früh M; Ng TL; Gounant V; Popat S; Diebold J; Sabari J; Zhu VW; Rothschild SI; Bironzo P; Martinez-Marti A; Curioni-Fontecedro A; Rosell R; Lattuca-Truc M; Wiesweg M; Besse B; Solomon B; Barlesi F; Schouten RD; Wakelee H; Camidge DR; Zalcman G; Novello S; Ou SI; Milia J; Gautschi O
Ann Oncol; 2019 Aug; 30(8):1321-1328. PubMed ID: 31125062
[TBL] [Abstract][Full Text] [Related]
7. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
8. First-Line Pembrolizumab Mono- or Combination Therapy of Non-Small Cell Lung Cancer: Baseline Metabolic Biomarkers Predict Outcomes.
Lang D; Ritzberger L; Rambousek V; Horner A; Wass R; Akbari K; Kaiser B; Kronbichler J; Lamprecht B; Gabriel M
Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885206
[TBL] [Abstract][Full Text] [Related]
9. Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study.
Lang D; Huemer F; Rinnerthaler G; Horner A; Wass R; Brehm E; Akbari K; Granitz M; Hutarew G; Kaiser B; Greil R; Lamprecht B
Target Oncol; 2019 Dec; 14(6):707-717. PubMed ID: 31654203
[TBL] [Abstract][Full Text] [Related]
10. Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study.
Yang X; Xiao Y; Zhou Y; Deng H; Yuan Z; Dong L; Lan J; Hu H; Huang J; Huang S
Ther Adv Med Oncol; 2023; 15():17588359231206282. PubMed ID: 37920256
[TBL] [Abstract][Full Text] [Related]
11. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
[TBL] [Abstract][Full Text] [Related]
12. Real-World Outcomes of Patients With Advanced Non-small Cell Lung Cancer Treated With Anti-PD1 Therapy on the Basis of PD-L1 Results in EBUS-TBNA vs Histological Specimens.
Tajarernmuang P; Ofiara L; Beaudoin S; Wang H; Benedetti A; Gonzalez AV
Chest; 2021 Aug; 160(2):743-753. PubMed ID: 33675792
[TBL] [Abstract][Full Text] [Related]
13. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
14. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract][Full Text] [Related]
15. Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancer.
Rich P; Mitchell RB; Schaefer E; Walker PR; Dubay JW; Boyd J; Oubre D; Page R; Khalil M; Sinha S; Boniol S; Halawani H; Santos ES; Brenner W; Orsini JM; Pauli E; Goldberg J; Veatch A; Haut M; Ghabach B; Bidyasar S; Quejada M; Khan W; Huang K; Traylor L; Akerley W
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706885
[TBL] [Abstract][Full Text] [Related]
16. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U; Tsourti Z; Vervita K; Peters S
Lung Cancer; 2019 Aug; 134():127-140. PubMed ID: 31319971
[TBL] [Abstract][Full Text] [Related]
17. Association of tumour burden with the efficacy of programmed cell death-1/programmed cell death ligand-1 inhibitors for treatment-naïve advanced non-small-cell lung cancer.
Suzuki S; Haratani K; Hayashi H; Chiba Y; Tanizaki J; Kato R; Mitani S; Kawanaka Y; Kurosaki T; Hasegawa Y; Okabe T; Tanaka K; Akashi Y; Ozaki T; Nishio K; Ito A; Nakagawa K
Eur J Cancer; 2022 Jan; 161():44-54. PubMed ID: 34922263
[TBL] [Abstract][Full Text] [Related]
18. Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment.
Tong J; Mao Y; Yang Z; Xu Q; Zheng Z; Zhang H; Wang J; Zhang S; Rong W; Zheng L
Cancer Manag Res; 2021; 13():4041-4053. PubMed ID: 34040444
[TBL] [Abstract][Full Text] [Related]
19. CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors.
Dall'Olio FG; Abbati F; Facchinetti F; Massucci M; Melotti B; Squadrilli A; Buti S; Formica F; Tiseo M; Ardizzoni A
Ther Adv Med Oncol; 2020; 12():1758835920952994. PubMed ID: 33193825
[TBL] [Abstract][Full Text] [Related]
20. PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer.
Yu H; Chen P; Xia L; Fu S; Chen C; Zhang X; He L; Zhang B; Zhou Y; Hong S
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34750245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
